Literature DB >> 8439962

Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

C H Spruck1, W M Rideout, A F Olumi, P F Ohneseit, A S Yang, Y C Tsai, P W Nichols, T Horn, G G Hermann, K Steven.   

Abstract

A distinct mutational spectrum for the p53 tumor suppressor gene in bladder carcinomas was established in patients with known exposures to cigarette smoke. Single-strand conformational polymorphism analysis of exons 5 through 8 of the p53 gene showed inactivating mutations in 16 of 40 (40%) bladder tumors from smokers and 13 of 40 (33%) tumors from lifetime nonsmokers. Overall, 13 of the 50 (26%) total point mutations discovered in this and previous work were G:C-->C:G transversions, a relatively rare mutational type in human tumors. In six tumors, identical AGA (Arg)-->ACA (Thr) point mutations at codon 280 were observed, suggesting a mutational hotspot in these tumors. Comparison of the mutational spectra from smokers and nonsmokers revealed no obvious differences in the types or positions of inactivating mutations; however, 5 of 15 tumors containing point mutations from cigarette smokers had double mutations, four of which were tandem mutations on the same allele. No double mutations were found in tumors from nonsmoking patients. None of the mutations in smokers were G:C-->T:A transversions, which would be anticipated for exposure to the suspected cigarette smoke carcinogen 4-aminobiphenyl. The results suggest that, although cigarette smoke exposure may not significantly alter the kinds of mutations sustained in the p53 gene, it may act to increase the extent of DNA damage per mutagenic event.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439962

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients.

Authors:  Noushin Taghavi; Firouzeh Biramijamal; Masoud Sotoudeh; Omeed Moaven; Hooman Khademi; Mohammad Reza Abbaszadegan; Reza Malekzadeh
Journal:  World J Gastroenterol       Date:  2010-10-21       Impact factor: 5.742

2.  Correlation of nuclear p53 over-expression with clinical and histopathological features of transitional cell bladder cancer.

Authors:  Z Sinik; T Alkibay; O Ataoğlu; G Akyol; H Tokuçoğlu; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 3.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

Review 4.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

5.  Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression.

Authors:  S Safarians; S P Rivera; M D Sternlicht; F Naeim; S H Barsky
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke.

Authors:  Arshad Rahmani; Mohammad Alzohairy; Habeeb Khadri; Ashish K Mandal; Moshahid A Rizvi
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

7.  Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer.

Authors:  A N Magewu; P A Jones
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 8.  Superficial bladder cancer.

Authors:  R R Hall
Journal:  BMJ       Date:  1994-04-02

Review 9.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

10.  Impact of age and gender on the clinicopathological characteristics of bladder cancer.

Authors:  Parag Gupta; Manoj Jain; Rakesh Kapoor; K Muruganandham; Aneesh Srivastava; Anil Mandhani
Journal:  Indian J Urol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.